Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) have received a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $30.35.

Several analysts recently commented on NRIX shares. Robert W. Baird assumed coverage on shares of Nurix Therapeutics in a report on Friday, September 6th. They set an “outperform” rating and a $26.00 price target for the company. HC Wainwright lifted their target price on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada dropped their price target on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Oppenheimer lifted their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, December 10th.

Nurix Therapeutics Stock Up 2.7 %

NRIX opened at $20.81 on Tuesday. The firm has a market capitalization of $1.47 billion, a P/E ratio of -7.15 and a beta of 2.11. The stock has a fifty day moving average of $23.63 and a 200-day moving average of $22.25. Nurix Therapeutics has a 12-month low of $7.65 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. On average, analysts expect that Nurix Therapeutics will post -2.81 earnings per share for the current fiscal year.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 3,546 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88. Following the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. The trade was a 9.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Christine Ring sold 3,290 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $25.00, for a total transaction of $82,250.00. Following the transaction, the insider now owns 24,592 shares of the company’s stock, valued at approximately $614,800. The trade was a 11.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,401 shares of company stock worth $437,453. 7.20% of the stock is owned by insiders.

Institutional Trading of Nurix Therapeutics

Hedge funds have recently modified their holdings of the company. Driehaus Capital Management LLC acquired a new stake in Nurix Therapeutics during the second quarter valued at approximately $26,778,000. Samlyn Capital LLC bought a new position in shares of Nurix Therapeutics during the 2nd quarter worth approximately $12,177,000. Sumitomo Mitsui Trust Group Inc. acquired a new stake in Nurix Therapeutics in the 3rd quarter valued at $12,432,000. FMR LLC grew its position in Nurix Therapeutics by 675.9% in the third quarter. FMR LLC now owns 586,902 shares of the company’s stock valued at $13,188,000 after acquiring an additional 511,256 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in Nurix Therapeutics during the third quarter worth $7,879,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.